Recently Viewed
Clear All₹10,732.60
As on 15-Apr-2020IST
Today’s Range
52 Week Range
Liquidity
Market cap
₹45,225 Cr
Revenue (TTM)
₹4,984 Cr
Net Profit (TTM)
₹622 Cr
ROE
25.9 %
ROCE
39.9 %
P/E Ratio
39.1
P/B Ratio
10.2
Industry P/E
22.74
EV/EBITDA
24
Div. Yield
1 %
Debt to Equity
0
Book Value
₹--
EPS
₹274.8
Face value
10
Shares outstanding
42,055,538
CFO
₹5,497.78 Cr
EBITDA
₹7,068.81 Cr
Net Profit
₹5,609.81 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glaxosmithkline [Merged]
| 29.2 | 21.5 | 23.0 | 49.0 | 26.5 | 11.3 | 21.5 |
|
BSE Sensex*
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
BSE FMCG#
| -12.4 | -7.1 | -11.8 | -5.9 | 3.0 | 7.6 | 8.9 |
|
Company
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|---|
|
Glaxosmithkline [Merged]
| 9.7 | 18.0 | 30.7 | -21.4 | 9.9 | 32.6 |
|
BSE Sensex
| 14.4 | 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE FMCG
| -3.6 | 10.5 | 31.5 | 3.3 | 1.4 | 18.3 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glaxosmithkline [Merged]
|
10,732.6 | 45,225.1 | 4,984.3 | 1,155.8 | 23.9 | 28 | 39.1 | 10.2 |
| 1,098.4 | 6,849.0 | 3,960.4 | 265.2 | 6.6 | 18.5 | 25.8 | 4.3 | |
| 978.9 | 21,777.0 | 9,624.4 | 348.3 | 6.4 | 19.6 | 62.5 | 11.5 | |
| 320.2 | 2,975.5 | 4,416.9 | 167.1 | 4.9 | 16.2 | 18.1 | 2.8 | |
| 32.5 | 92.3 | 338.8 | 22.4 | 1.9 | 55.1 | 4.1 | 1.6 | |
| 201.7 | 2,528.5 | 3,790.4 | 129.0 | 5.0 | 12.1 | 19.6 | 2.1 | |
| 9.0 | 32.1 | 0.6 | -0.1 | -45.5 | -1 | -- | 4.8 | |
| 299.3 | 321.8 | 326.2 | 15.7 | 11.6 | 11.7 | 20.5 | 2.3 | |
| 4,680.6 | 3,368.7 | 1,359.7 | 122.3 | 11.4 | 16.5 | 27.6 | 4.7 | |
| 29.8 | 60.9 | 167.2 | -7.2 | -3.9 | -10.9 | -- | 1.0 |
The Backing of a Resilient Balance Sheet
5 min read•By Jugal Harpalani
2 min read•By Mohammed Ekramul Haque
3 min read•By Mohammed Ekramul Haque
3 min read•By Mohammed Ekramul Haque and Vikas Vardhan
2 min read•By Mohammed Ekramul Haque
1 min read•By Vikas Vardhan
Manufacture of malted foods including foods for infants and handicapped
Incorporated
1958
Chairman
P Dwarakanath
Managing Director
Navneet Saluja
Group
Glaxosmithkline - MNC
Headquarters
Nabha, Punjab
Website
Annual Reports
The share price of Glaxosmithkline Consumer Healthcare Ltd [Merged] is ₹10,732.60 (NSE) and ₹10,753.65 (BSE) as of 15-Apr-2020 IST. Glaxosmithkline Consumer Healthcare Ltd [Merged] has given a return of 26.53% in the last 3 years.
The P/E ratio of Glaxosmithkline Consumer Healthcare Ltd [Merged] is 39.13 times as on 15-Apr-2020, a 72 premium to its peers’ median range of 22.74 times.
The P/B ratio of Glaxosmithkline Consumer Healthcare Ltd [Merged] is 10.19 times as on 15-Apr-2020, a 170 premium to its peers’ median range of 3.77 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2019
|
30.86
|
7.41
|
|
2018
|
36.61
|
7.36
|
|
2017
|
33.04
|
6.95
|
|
2016
|
36.93
|
9.07
|
|
2015
|
45.40
|
12.54
|
The 52-week high and low of Glaxosmithkline Consumer Healthcare Ltd [Merged] are Rs -- and Rs -- as of 19-Mar-2026.
Glaxosmithkline Consumer Healthcare Ltd [Merged] has a market capitalisation of ₹ 45,225 Cr as on 15-Apr-2020. As per SEBI classification, it is a company.
Before investing in Glaxosmithkline Consumer Healthcare Ltd [Merged], assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.